| Literature DB >> 20946686 |
Amy R Sapkota1, Morenike E Coker, Rachel E Rosenberg Goldstein, Nancy L Atkinson, Shauna J Sweet, Priscilla O Sopeju, Modupe T Ojo, Elizabeth Otivhia, Olayemi O Ayepola, Olufunmiso O Olajuyigbe, Laura Shireman, Paul S Pottinger, Kayode K Ojo.
Abstract
BACKGROUND: Self-medication with antibiotics is an important factor contributing to the development of bacterial antibiotic resistance. The purpose of this study was to evaluate the prevalence of self-medication with antibiotics for the treatment of menstrual symptoms among university women in Southwest Nigeria.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20946686 PMCID: PMC2965722 DOI: 10.1186/1471-2458-10-610
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Study population (n = 706) characteristics
| Demographic Characteristics | n | % |
|---|---|---|
| University | ||
| Babcock University | 237 | 33.6 |
| Covenant University | 167 | 23.7 |
| University of Ibadan | 149 | 21.1 |
| Obafemi Awolowo University | 153 | 21.7 |
| Education Level | ||
| Preliminary level (Pre-college) | 3 | 0.42 |
| Freshman (100 level) | 166 | 23.5 |
| Sophomore (200 level) | 194 | 27.5 |
| Junior (300 level) | 171 | 24.2 |
| Senior (400 level) | 73 | 10.3 |
| Final year of Pharmacy, Law, or Engineering | 45 | 6.4 |
| Final year of Medical School | 2 | 0.3 |
| Masters or Doctorate | 26 | 3.7 |
| Missing data | 26 | 3.7 |
| Area of Concentration | ||
| Lab Science, Medicine | 285 | 40.4 |
| Social Sciences | 135 | 19.1 |
| Humanities (Arts, Languages) | 97 | 13.7 |
| Business and Finance | 102 | 14.5 |
| Technology | 53 | 7.5 |
| Missing data | 35 | 5.0 |
| Age | ||
| < 17 | 16 | 2.3 |
| 17-20 | 330 | 46.7 |
| 21-24 | 250 | 35.4 |
| 25-29 | 66 | 9.4 |
| 30-34 | 16 | 2.3 |
| 35-39 | 6 | 0.9 |
| ≥ 40 | 1 | 0.1 |
| Missing data | 21 | 3.0 |
| Marital Status | ||
| Single | 609 | 86.3 |
| Engaged, Married, Separated, | ||
| Divorced or Widowed | 74 | 10.5 |
| Missing data | 23 | 3.3 |
Results of multivariate analysis of factors that may influence self-medication with antibiotics for the treatment of menstrual symptoms.
| Independent Variable | Odds Ratio | 95% Confidence Interval | |
|---|---|---|---|
| Cramps | |||
| No (n = 187) | 1.00 | - | - |
| Yes (Mild to severe) (n = 435) | 0.57 | (0.36 - 0.91) | 0.02 |
| Heavy flow/heavy bleeding | |||
| No (n = 186) | 1.00 | - | - |
| Yes (Mild to severe) (n = 436) | 1.64 | (1.01-2.67) | 0.05 |
| Pimples/acne | |||
| No (n = 182) | 1.00 | - | - |
| Yes (Mild to severe) (n = 456) | 1.57 | (0.98-2.54) | 0.06 |
| Education level | |||
| Preliminary and undergraduate levels (n = 607) | 1.00 | - | - |
| Graduate level (n = 73) | 0.36 | (0.14 - 0.91) | 0.03 |
| Major | |||
| Lab science, public health or medicine (n = 285) | 1.00 | - | - |
| Non-science (n = 386) | 1.58 | (1.03 - 2.50) | 0.04 |
| Use of pain relievers to relieve menses symptoms | |||
| No (n = 411) | 1.00 | - | - |
| Yes (n = 276) | 3.17 | (2.07 - 4.86) | <0.001 |
| Age | |||
| ≤ 20 (n = 346) | 1.00 | - | - |
| 21-29 (n = 316) | 1.09 | (0.68-1.74) | 0.72 |
| ≥ 30 (n = 23) | 1.78 | (0.31-10.1) | 0.52 |
| University | |||
| Babcock University (n = 237) | 1.00 | - | - |
| Covenant University (n = 167) | 1.13 | (0.62-2.07) | 0.68 |
| University of Ibadan (n = 149) | 1.61 | (0.90-2.88) | 0.10 |
| Obafemi Awolowo University (n = 153) | 1.26 | (0.69-2.28) | 0.45 |
Figure 1Prevalence of self-medication with antibiotics for the treatment of menstrual symptoms among University women in Southwest Nigeria by major area of study and symptoms.
Number of study participants using specific antibiotics to treat specific menstrual symptoms (n, (%, 95% confidence interval)), and estimates of the overall prevalence of use for each antibiotic for one or more menstrual symptoms (%, 95% confidence interval)
| Symptoms | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Antibiotic | Cramps | Weight gain, bloating | Heavy flow, heavy bleeding | Headaches | Pimples, acne | Aggression, moodiness | Tender, painful breasts | Backache, joint or muscle pain | Other | Prevalence of use for ≥ 1 menstrual symptom |
| Ampicillin | 4 (0.6, 0.01-1.1) | 5 (0.7, 0.08-1.3) | 6 (0.9, 0.1-1.5) | 2 (0.3, 0.1-0.6) | 2 (0.3, 0.1-0.6) | 0 | 1 (0.14, -0.01-0.4) | 2 (0.3, 0.1-0.6) | 3 (0.4, 0.05-0.9) | 2.6 (1.4-3.7) |
| Ampiclox (Ampicillin + Cloxacillin) | 2 (0.3, 0.1-0.6) | 0 | 6 (0.9, 0.1-1.5) | 1 (0.14, -0.01-0.4) | 2 (0.3, 0.1-0.6) | 0 | 0 | 0 | 1 (0.14, -0.01-0.4) | 2.0 (0.95-3.0) |
| Pefloxacin | 1 (0.14, -0.01-0.4) | 3 (0.4, 0.05-0.9) | 1 (0.14, -0.01-0.4) | 0 | 0 | 0 | 0 | 1 (0.14, -0.01-0.4) | 0 | 0.9 (0.2-1.5) |
| Amoxicillin | 2 (0.3, 0.1-0.6) | 1 (0.14, -0.01-0.4) | 3 (0.4, 0.05-0.9) | 3 (0.4, 0.05-0.9) | 0 | 0 | 0 | 0 | 0 | 1.3 (0.4-2.1) |
| Augmentin | 1 (0.14, -0.01-0.4) | 1 (0.14, -0.01-0.4) | 2 (0.3, 0.1-0.6) | 0 | 0 | 0 | 0 | 0 | 1 (0.14, -0.01-0.4) | 0.7 (0.1-1.3) |
| Ofloxacin | 2 (0.3, 0.1-0.6) | 1 (0.14, -0.01-0.4) | 2 (0.3, 0.1-0.6) | 2 (0.3, 0.1-0.6) | 0 | 0 | 0 | 0 | 0 | 1.1 (0.4-1.9) |
| Tetracycline | 6 (0.9, 0.1-1.5) | 1 (0.14, -0.01-0.4) | 4 (0.6, 0.01-1.1) | 1 (0.14, -0.01-0.4) | 0 | 0 | 1 (0.14, -0.01-0.4) | 2 (0.3, 0.1-0.6) | 7 (1.0, 0.2-1.7) | 2.7 (1.5-3.9) |
| Ciprofloxacin | 2 (0.3, 0.1-0.6) | 1 (0.14, -0.01-0.4) | 1 (0.14, -0.01-0.4) | 2 (0.3, 0.1-0.6) | 1 (0.14, -0.01-0.4) | 0 | 0 | 1 (0.14, -0.01-0.4) | 4 (0.6, 0.01-1.1) | 1.4 (0.5-2.3) |
| Metronidazole | 6 (0.9, 0.1-1.5) | 1 (0.14, -0.01-0.4) | 2 (0.3, 0.1-0.6) | 1 (0.14, -0.01-0.4) | 0 | 1 (0.14, -0.01-0.4) | 1 (0.14, -0.01-0.4) | 1 (0.14, -0.01-0.4) | 1 (0.14, -0.01-0.4) | 3.0 (1.7-4.2) |
| Cotrimoxazole | 3 (0.4, 0.05-0.9) | 0 | 0 | 3 (0.4, 0.05-0.9) | 1 (0.14, -0.01-0.4) | 0 | 1 (0.14, -0.01-0.4) | 1 (0.14, -0.01-0.4) | 2 (0.3, 0.1-0.6) | 1.6 (0.6-2.5) |
| Streptomycin | 1 (0.14, -0.01-0.4) | 0 | 2 (0.3, 0.1-0.6) | 1 (0.14, -0.01-0.4) | 0 | 0 | 0 | 0 | 0 | 0.6 (0.01-1.1) |
| Gentamicin | 3 (0.4, 0.05-0.9) | 1 (0.14, -0.01-0.4) | 0 | 2 (0.3, 0.1-0.6) | 1 (0.14, -0.01-0.4) | 0 | 0 | 0 | 0 | 1.0 (0.3-1.7) |
Figure 2Individuals who recommended the use of antibiotics to treat menstrual symptoms and individuals or entities who provided antibiotics to study participants.